Q2 EPS Estimates for Henry Schein Reduced by Zacks Research

Henry Schein, Inc. (NASDAQ:HSIC) – Investment analysts at Zacks Research decreased their Q2 2025 earnings per share estimates for shares of Henry Schein in a research note issued to investors on Wednesday, April 2nd. Zacks Research analyst R. Department now expects that the company will earn $1.19 per share for the quarter, down from their prior estimate of $1.21. The consensus estimate for Henry Schein’s current full-year earnings is $4.74 per share. Zacks Research also issued estimates for Henry Schein’s Q2 2025 earnings at $1.19 EPS, FY2025 earnings at $4.83 EPS, FY2025 earnings at $4.83 EPS, Q1 2026 earnings at $1.31 EPS, Q1 2026 earnings at $1.31 EPS, Q2 2026 earnings at $1.35 EPS, Q2 2026 earnings at $1.35 EPS, Q4 2026 earnings at $1.38 EPS, Q4 2026 earnings at $1.38 EPS, FY2026 earnings at $5.29 EPS, FY2026 earnings at $5.29 EPS, FY2027 earnings at $5.69 EPS and FY2027 earnings at $5.69 EPS.

A number of other analysts also recently weighed in on the company. Wells Fargo & Company assumed coverage on Henry Schein in a report on Friday, February 14th. They issued an “equal weight” rating and a $80.00 price objective for the company. Bank of America upgraded shares of Henry Schein from an “underperform” rating to a “buy” rating and raised their price target for the stock from $69.00 to $84.00 in a report on Monday, January 6th. Barrington Research reaffirmed an “outperform” rating and issued a $90.00 price objective on shares of Henry Schein in a research note on Wednesday, February 26th. Jefferies Financial Group lifted their target price on shares of Henry Schein from $77.00 to $80.00 and gave the stock a “hold” rating in a research note on Thursday, January 23rd. Finally, UBS Group dropped their target price on shares of Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a report on Wednesday, February 26th. Six analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Henry Schein has an average rating of “Moderate Buy” and a consensus price target of $81.10.

Henry Schein Price Performance

HSIC stock opened at $65.47 on Friday. The company has a market capitalization of $8.13 billion, a P/E ratio of 26.94, a PEG ratio of 2.13 and a beta of 0.84. The company has a fifty day moving average price of $73.96 and a 200-day moving average price of $72.57. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. Henry Schein has a 52-week low of $63.00 and a 52-week high of $82.49.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, February 25th. The company reported $1.19 EPS for the quarter, missing the consensus estimate of $1.23 by ($0.04). The firm had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.25 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. Henry Schein’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.66 earnings per share.

Institutional Trading of Henry Schein

Several hedge funds have recently made changes to their positions in HSIC. Versant Capital Management Inc increased its position in shares of Henry Schein by 274.6% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $32,000 after buying an additional 335 shares during the period. Investment Management Corp VA ADV bought a new stake in shares of Henry Schein during the 4th quarter valued at about $32,000. Venturi Wealth Management LLC boosted its position in shares of Henry Schein by 3,347.1% during the 4th quarter. Venturi Wealth Management LLC now owns 586 shares of the company’s stock valued at $41,000 after acquiring an additional 569 shares during the last quarter. Quent Capital LLC grew its holdings in shares of Henry Schein by 91.2% during the fourth quarter. Quent Capital LLC now owns 677 shares of the company’s stock worth $47,000 after purchasing an additional 323 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its position in shares of Henry Schein by 23.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 759 shares of the company’s stock worth $52,000 after purchasing an additional 143 shares during the last quarter. 96.62% of the stock is currently owned by institutional investors.

Insider Activity at Henry Schein

In other news, CEO Bradford C. Connett sold 4,036 shares of the stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total value of $287,161.40. Following the completion of the sale, the chief executive officer now owns 62,688 shares in the company, valued at $4,460,251.20. This represents a 6.05 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Philip A. Laskawy sold 2,604 shares of the company’s stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total value of $184,988.16. Following the completion of the transaction, the director now directly owns 24,805 shares of the company’s stock, valued at approximately $1,762,147.20. This represents a 9.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by corporate insiders.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.